Marketing-authorisation holder
MSD Sub Merck
15 medicines in 1 country, as authorisation holder.
Loading…
Marketing-authorisation holder
15 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
15 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BRIDION200mg base/2ml (eq 100mg base/ml) | 500mg base/5ml (eq 100mg base/ml) · Solution | Sugammadex | United States | Marketed | 2015 |
| INTEGRILIN2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 75MG/100ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Injectable | Eptifibatide | United States | Not marketed | 1998 |
| INVANZ1gm base/vial · Injectable | Ertapenem | United States | Marketed | 2001 |
| ISENTRESS400mg base · Tablet | Raltegravir | United States | Marketed | 2007 |
| ISENTRESS100mg base | 25mg base · Tablet, chewable | Raltegravir | United States | Marketed | 2011 |
| ISENTRESS100mg base/packet · Powder | Raltegravir | United States | Marketed | 2013 |
| ISENTRESS HD600mg base · Tablet | Raltegravir | United States | Marketed | 2007 |
| JANUMET1gm; 50mg base | 500mg; 50mg base · Tablet | Metformin, Sitagliptin | United States | Marketed | 2007 |
| JANUMET XR1gm; 100mg base | 1gm; 50mg base | 500mg; 50mg base · Tablet, extended release | Metformin, Sitagliptin | United States | Marketed | 2012 |
| SEGLUROMET2.5mg; 1gm | 2.5mg; 500mg | 7.5mg; 1gm | 7.5mg; 500mg · Tablet | Ertugliflozin, Metformin | United States | Marketed | 2017 |
| STEGLATRO15mg | 5mg · Tablet | Ertugliflozin | United States | Marketed | 2017 |
| STEGLUJAN15mg; 100mg base | 5mg; 100mg base · Tablet | Ertugliflozin, Sitagliptin | United States | Marketed | 2017 |
| TRUSOPT2% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution/drops | Dorzolamide | United States | Not marketed | 1994 |
| ZEPATIER50mg; 100mg · Tablet | Elbasvir, Grazoprevir | United States | Not marketed | 2016 |
| ZOLINZA100mg · Capsule | Vorinostat | United States | Marketed | 2006 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 15 | 15 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Keep MSD Sub Merck’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a callOther companies in the same group.